The Time Course of Repolarization Effects of Intravenous Dofetilide: A Pure Class III Antiarrhythmic Agent

•Dofetilide administered intravenously has a rapid onset of action and the dose of dofetilide is proportional to the prolongation in cardiac repolarization as represented by an increase in QTc interval.•These findings suggest the potential clinical utility of an IV formulation of dofetilide. Dofetil...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of cardiology Vol. 257; pp. 38 - 42
Main Authors Molnar, Janos, Somberg, John C.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 15.12.2025
Online AccessGet full text
ISSN0002-9149
1879-1913
DOI10.1016/j.amjcard.2025.07.040

Cover

Loading…
Abstract •Dofetilide administered intravenously has a rapid onset of action and the dose of dofetilide is proportional to the prolongation in cardiac repolarization as represented by an increase in QTc interval.•These findings suggest the potential clinical utility of an IV formulation of dofetilide. Dofetilide’s action is inhibition of the potassium channel (IKr) which causes a delay of repolarization as seen on the ECG as QTc prolongation and is its mechanism of antiarrhythmic action. Thus, the time to repolarization prolongation is critical in evaluating the onset of potential antiarrhythmic action. To determine the extent and time course of Dofetilide administered intravenously on cardiac repolarization. Methods: Dofetilide naive healthy subjects 18–45 years received a single dose of 500 mcg dofetilide administered IV over 2.5 hours by constant infusion rate. 12-lead digital Holters recorded the ECG and 20 blood samples were collected. A validated liquid chromatographic method measured dofetilide plasma concentration. The QT intervals were measured by the median beat method from 10‑sec recordings. The Bazett formula was used for QT correction (QTc). Dofetilide concentration continuously increased from the start to the end of the infusion, then gradually decreased. The QTc showed similar dynamics with very early prolongation. At 15 min 50 mcg dofetilide was administered, 1 tenth the recommended dose, with the QTc increasing by 11 ± 10 ms (p = 0.001) indicating early effect on repolarization. There was a strong linear correlation between dofetilide concentrations and QTc intervals (r = 0.95, p < 0.001) with every 1 nanogram increase in plasma concentration resulting in a 17 ms QTc prolongation. The early effect of IV dofetilide on cardiac repolarization suggests dofetilide clinically utility with an immediate antiarrhythmic action. Future clinical studies are indicated to determine optimum dosing, efficacy as well as safety. [Display omitted]
AbstractList •Dofetilide administered intravenously has a rapid onset of action and the dose of dofetilide is proportional to the prolongation in cardiac repolarization as represented by an increase in QTc interval.•These findings suggest the potential clinical utility of an IV formulation of dofetilide. Dofetilide’s action is inhibition of the potassium channel (IKr) which causes a delay of repolarization as seen on the ECG as QTc prolongation and is its mechanism of antiarrhythmic action. Thus, the time to repolarization prolongation is critical in evaluating the onset of potential antiarrhythmic action. To determine the extent and time course of Dofetilide administered intravenously on cardiac repolarization. Methods: Dofetilide naive healthy subjects 18–45 years received a single dose of 500 mcg dofetilide administered IV over 2.5 hours by constant infusion rate. 12-lead digital Holters recorded the ECG and 20 blood samples were collected. A validated liquid chromatographic method measured dofetilide plasma concentration. The QT intervals were measured by the median beat method from 10‑sec recordings. The Bazett formula was used for QT correction (QTc). Dofetilide concentration continuously increased from the start to the end of the infusion, then gradually decreased. The QTc showed similar dynamics with very early prolongation. At 15 min 50 mcg dofetilide was administered, 1 tenth the recommended dose, with the QTc increasing by 11 ± 10 ms (p = 0.001) indicating early effect on repolarization. There was a strong linear correlation between dofetilide concentrations and QTc intervals (r = 0.95, p < 0.001) with every 1 nanogram increase in plasma concentration resulting in a 17 ms QTc prolongation. The early effect of IV dofetilide on cardiac repolarization suggests dofetilide clinically utility with an immediate antiarrhythmic action. Future clinical studies are indicated to determine optimum dosing, efficacy as well as safety. [Display omitted]
Dofetilide's action is inhibition of the potassium channel (IKr) which causes a delay of repolarization as seen on the ECG as QTc prolongation and is its mechanism of antiarrhythmic action. Thus, the time to repolarization prolongation is critical in evaluating the onset of potential antiarrhythmic action. To determine the extent and time course of Dofetilide administered intravenously on cardiac repolarization. Methods: Dofetilide naive healthy subjects 18-45 years received a single dose of 500 mcg dofetilide administered IV over 2.5 hours by constant infusion rate. 12-lead digital Holters recorded the ECG and 20 blood samples were collected. A validated liquid chromatographic method measured dofetilide plasma concentration. The QT intervals were measured by the median beat method from 10‑sec recordings. The Bazett formula was used for QT correction (QTc). Dofetilide concentration continuously increased from the start to the end of the infusion, then gradually decreased. The QTc showed similar dynamics with very early prolongation. At 15 min 50 mcg dofetilide was administered, 1 tenth the recommended dose, with the QTc increasing by 11 ± 10 ms (p = 0.001) indicating early effect on repolarization. There was a strong linear correlation between dofetilide concentrations and QTc intervals (r = 0.95, p < 0.001) with every 1 nanogram increase in plasma concentration resulting in a 17 ms QTc prolongation. The early effect of IV dofetilide on cardiac repolarization suggests dofetilide clinically utility with an immediate antiarrhythmic action. Future clinical studies are indicated to determine optimum dosing, efficacy as well as safety.
Author Somberg, John C.
Molnar, Janos
Author_xml – sequence: 1
  givenname: Janos
  surname: Molnar
  fullname: Molnar, Janos
– sequence: 2
  givenname: John C.
  orcidid: 0000-0002-4518-6203
  surname: Somberg
  fullname: Somberg, John C.
  email: johnsomberg1@comcast.net
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40769288$$D View this record in MEDLINE/PubMed
BookMark eNqNkNFq2zAUhsXoaNKuj7ChF7AnybZkD8YIWdcaCi0jvRaKdLTIs6UgOYX06eeQtBe96a7EQf__cc53gc588IDQZ0pySij_2uVq6LSKJmeEVTkROSnJBzSntWgy2tDiDM0JISxraNnM0EVK3TRSWvFzNCuJ4A2r6znqVhvAKzcAXoZdTICDxb9hG3oV3bMaXfD42lrQYzr8tH6M6gl82CX8M1gYXe8MfMML_LCLE6JXKeG2bfHCj07FuNmPm8FpvPgDfvyEPlrVJ7g6vZfo8df1anmb3d3ftMvFXaZZRceMC1pbZk3JuFGNIZqtCTXcUiWqoqZa1YJqwWteMGWUWBe6XAvRNJqrShfGFpfoy5G73a0HMHIb3aDiXr4cPQWqY0DHkFIE-xqhRB7kyk6e5MqDXEmEnOROvR_HHkzbPzmIMmkHXoNxcTIkTXDvEr6_IejeeadV_xf2_9H_B4c6mZk
Cites_doi 10.1016/0002-9149(86)90692-2
10.1111/j.1365-2125.1991.tb05572.x
10.1097/00005344-199220002-00015
10.1016/S0002-9149(99)00927-3
10.1016/S0735-1097(96)00506-2
10.1161/CIRCULATIONAHA.106.180200
10.3390/jcm13206094
10.1046/j.1365-2125.2000.00243.x
10.1159/000316050
10.1016/j.vascn.2005.07.002
10.1046/j.1365-2125.2002.01627.x
10.1592/phco.20.9.776.35208
10.1016/0002-9149(92)90295-A
ContentType Journal Article
Copyright 2025 Elsevier Inc.
Copyright © 2025 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2025 Elsevier Inc.
– notice: Copyright © 2025 Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
NPM
DOI 10.1016/j.amjcard.2025.07.040
DatabaseName CrossRef
PubMed
DatabaseTitle CrossRef
PubMed
DatabaseTitleList

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1879-1913
EndPage 42
ExternalDocumentID 40769288
10_1016_j_amjcard_2025_07_040
S0002914925004503
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
23M
4.4
457
4G.
5RE
5VS
6J9
7-5
71M
7RV
7X7
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAQFI
AATTM
AAWTL
AAXKI
AAXUO
ABBQC
ABFNM
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABPPZ
ACDAQ
ACGFO
ACGFS
ACIEU
ACIUM
ACIWK
ACPRK
ACRLP
ACVFH
ADBBV
ADCNI
ADEZE
ADFRT
ADUKH
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGUBO
AGYEJ
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
AXJTR
BENPR
BKOJK
BKOMP
BLXMC
BNPGV
CS3
EBS
EFJIC
EFKBS
EO9
EP2
EP3
EX3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
IH2
IHE
J1W
J5H
K-O
KOM
L7B
M2O
MO0
N9A
O-L
O9-
OA.
OAUVE
OL~
OZT
P-8
P-9
P2P
PC.
Q38
ROL
RPZ
SDF
SDG
SEL
SES
SJN
SPCBC
SSH
SSZ
T5K
TWZ
UNMZH
UV1
WH7
WOW
YFH
YOC
YZZ
Z5R
~G-
EFLBG
.55
.GJ
1CY
3O-
53G
88E
8FI
8FJ
8G5
AAQQT
AAQXK
AAYWO
AAYXX
ABUWG
ABWVN
ABXDB
ACRPL
ADMUD
ADNMO
AFFNX
AFKRA
AGQPQ
AHHHB
ASPBG
AVWKF
AZFZN
AZQEC
BKEYQ
BPHCQ
BVXVI
CCPQU
CITATION
DWQXO
EJD
EMOBN
FEDTE
FGOYB
FYUFA
G-2
GNUQQ
GUQSH
HEB
HMCUK
HMK
HMO
HVGLF
HZ~
M1P
M29
M41
NAPCQ
OHT
OVD
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
R2-
SAE
SV3
TEORI
UKHRP
WUQ
X7M
XPP
YQJ
YYP
ZGI
ZXP
NPM
ID FETCH-LOGICAL-c251t-6718f2fd426da9d0c2b01d6f1a75381ca871c768632ada7b3c4b7799c6a5c3df3
IEDL.DBID .~1
ISSN 0002-9149
IngestDate Thu Aug 28 04:49:10 EDT 2025
Wed Sep 03 16:40:38 EDT 2025
Sat Sep 06 17:21:13 EDT 2025
Sat Aug 30 06:04:46 EDT 2025
IsPeerReviewed true
IsScholarly true
Language English
License Copyright © 2025 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c251t-6718f2fd426da9d0c2b01d6f1a75381ca871c768632ada7b3c4b7799c6a5c3df3
ORCID 0000-0002-4518-6203
PMID 40769288
PageCount 5
ParticipantIDs pubmed_primary_40769288
crossref_primary_10_1016_j_amjcard_2025_07_040
elsevier_sciencedirect_doi_10_1016_j_amjcard_2025_07_040
elsevier_clinicalkey_doi_10_1016_j_amjcard_2025_07_040
PublicationCentury 2000
PublicationDate 2025-12-15
PublicationDateYYYYMMDD 2025-12-15
PublicationDate_xml – month: 12
  year: 2025
  text: 2025-12-15
  day: 15
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The American journal of cardiology
PublicationTitleAlternate Am J Cardiol
PublicationYear 2025
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Sedgwick, Rasmussen, Cobbe (bib0011) 1992; 70
FDA Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Accessed June 9, 2025.
Ollerstam, Visser, Persson, Eklund, Nilsson, Forsberg, Wiklund, Gabrielsson, Duker, Al-Saffa (bib0015) 2006; 53
Tikosyn_Product_Monograph. Accessed June 9, 2025.
Șorodoc, Indrei, Dobroghii, Asaftei, Ceasovschih, Constantin, Lionte, Morărașu, Diaconu, Șorodoc (bib0001) 2024; 13
Sedgwick, Rasmussen, Walker, Cobbe (bib0010) 1991; 31
Rasmussen, Allen, Blackburn, Butrous, Dalrymple (bib0014) 1992; 20
TIKOSYN – dofetilide- Drug product label. Accessed June 9, 2025
.
Falk, Pollak, Singh, Friedrich (bib0017) 1997; 29
(bib0009) 2007; 115
Shah (bib0013) 2002; 54
Somberg, Preston, Ranade, Molnar (bib0003) 2010; 116
Allen, Nichols, Oliver (bib0007) 2000; 50
Lindeboom, Kingma, Crijns, Dunselman (bib0016) 2000; 85
Wang, Bergstrand, Thompson, Siddoway, Duff, Woosley, Roden (bib0004) 1986; 57
Lenz, Hilleman (bib0006) 2000; 20
BETAPACE- sotalol hydrochloride tablet – Drug product label. Accessed June 9, 2025.
Lindeboom (10.1016/j.amjcard.2025.07.040_bib0016) 2000; 85
10.1016/j.amjcard.2025.07.040_bib0005
Shah (10.1016/j.amjcard.2025.07.040_bib0013) 2002; 54
10.1016/j.amjcard.2025.07.040_bib0002
Allen (10.1016/j.amjcard.2025.07.040_bib0007) 2000; 50
10.1016/j.amjcard.2025.07.040_bib0008
Sedgwick (10.1016/j.amjcard.2025.07.040_bib0010) 1991; 31
Falk (10.1016/j.amjcard.2025.07.040_bib0017) 1997; 29
(10.1016/j.amjcard.2025.07.040_bib0009) 2007; 115
10.1016/j.amjcard.2025.07.040_bib0012
Ollerstam (10.1016/j.amjcard.2025.07.040_bib0015) 2006; 53
Somberg (10.1016/j.amjcard.2025.07.040_bib0003) 2010; 116
Rasmussen (10.1016/j.amjcard.2025.07.040_bib0014) 1992; 20
Wang (10.1016/j.amjcard.2025.07.040_bib0004) 1986; 57
Lenz (10.1016/j.amjcard.2025.07.040_bib0006) 2000; 20
Șorodoc (10.1016/j.amjcard.2025.07.040_bib0001) 2024; 13
Sedgwick (10.1016/j.amjcard.2025.07.040_bib0011) 1992; 70
References_xml – reference: Tikosyn_Product_Monograph. Accessed June 9, 2025.
– volume: 20
  start-page: S96
  year: 1992
  end-page: S105
  ident: bib0014
  article-title: Dofetilide, a novel class III antiarrhythmic agent
  publication-title: J Cardiovasc Pharmacol
– reference: BETAPACE- sotalol hydrochloride tablet – Drug product label. Accessed June 9, 2025.
– volume: 53
  start-page: 174
  year: 2006
  end-page: 183
  ident: bib0015
  article-title: Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs
  publication-title: J Pharmacol Toxicol Methods
– volume: 54
  start-page: 188
  year: 2002
  end-page: 202
  ident: bib0013
  article-title: The significance of QT interval in drug development
  publication-title: Br J Clin Pharmacol
– volume: 85
  start-page: 1031
  year: 2000
  end-page: 1033
  ident: bib0016
  article-title: Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter
  publication-title: Am J Cardiol
– volume: 115
  start-page: 1306
  year: 2007
  end-page: 1324
  ident: bib0009
  article-title: Recommendations for the standardization and interpretation of the electrocardiogram: part I: the electrocardiogram and its technology: a scientific Statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society endorsed by the International Society for Computerized Electrocardiology
  publication-title: Circulation
– reference: .
– volume: 116
  start-page: 219
  year: 2010
  end-page: 225
  ident: bib0003
  article-title: QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol
  publication-title: Cardiology
– volume: 13
  start-page: 6094
  year: 2024
  ident: bib0001
  article-title: Amiodarone therapy: updated practical insights
  publication-title: J Clin Med
– volume: 50
  start-page: 247
  year: 2000
  end-page: 253
  ident: bib0007
  article-title: The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing
  publication-title: Br J Clin Pharmacol
– volume: 31
  start-page: 515
  year: 1991
  end-page: 519
  ident: bib0010
  article-title: Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug
  publication-title: Br J Clin Pharmacol
– reference: FDA Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Accessed June 9, 2025.
– volume: 20
  start-page: 776
  year: 2000
  end-page: 786
  ident: bib0006
  article-title: Dofetilide, a new class III antiarrhythmic agent
  publication-title: Pharmacotherapy
– reference: TIKOSYN – dofetilide- Drug product label. Accessed June 9, 2025
– volume: 57
  start-page: 1160
  year: 1986
  end-page: 1165
  ident: bib0004
  article-title: Concentration-dependent pharmacologic properties of sotalol
  publication-title: Am J Cardiol
– volume: 29
  start-page: 385
  year: 1997
  end-page: 390
  ident: bib0017
  article-title: Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous dofetilide investigators
  publication-title: J Am Coll Cardiol
– volume: 70
  start-page: 1432
  year: 1992
  end-page: 1437
  ident: bib0011
  article-title: Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris
  publication-title: Am J Cardiol
– volume: 57
  start-page: 1160
  issue: 13
  year: 1986
  ident: 10.1016/j.amjcard.2025.07.040_bib0004
  article-title: Concentration-dependent pharmacologic properties of sotalol
  publication-title: Am J Cardiol
  doi: 10.1016/0002-9149(86)90692-2
– volume: 31
  start-page: 515
  issue: 5
  year: 1991
  ident: 10.1016/j.amjcard.2025.07.040_bib0010
  article-title: Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/j.1365-2125.1991.tb05572.x
– volume: 20
  start-page: S96
  issue: Suppl 2
  year: 1992
  ident: 10.1016/j.amjcard.2025.07.040_bib0014
  article-title: Dofetilide, a novel class III antiarrhythmic agent
  publication-title: J Cardiovasc Pharmacol
  doi: 10.1097/00005344-199220002-00015
– volume: 85
  start-page: 1031
  issue: 8
  year: 2000
  ident: 10.1016/j.amjcard.2025.07.040_bib0016
  article-title: Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter
  publication-title: Am J Cardiol
  doi: 10.1016/S0002-9149(99)00927-3
– ident: 10.1016/j.amjcard.2025.07.040_bib0008
– volume: 29
  start-page: 385
  issue: 2
  year: 1997
  ident: 10.1016/j.amjcard.2025.07.040_bib0017
  article-title: Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous dofetilide investigators
  publication-title: J Am Coll Cardiol
  doi: 10.1016/S0735-1097(96)00506-2
– volume: 115
  start-page: 1306
  issue: 10
  year: 2007
  ident: 10.1016/j.amjcard.2025.07.040_bib0009
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.106.180200
– volume: 13
  start-page: 6094
  issue: 20
  year: 2024
  ident: 10.1016/j.amjcard.2025.07.040_bib0001
  article-title: Amiodarone therapy: updated practical insights
  publication-title: J Clin Med
  doi: 10.3390/jcm13206094
– ident: 10.1016/j.amjcard.2025.07.040_bib0005
– volume: 50
  start-page: 247
  issue: 3
  year: 2000
  ident: 10.1016/j.amjcard.2025.07.040_bib0007
  article-title: The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing
  publication-title: Br J Clin Pharmacol
  doi: 10.1046/j.1365-2125.2000.00243.x
– volume: 116
  start-page: 219
  issue: 3
  year: 2010
  ident: 10.1016/j.amjcard.2025.07.040_bib0003
  article-title: QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol
  publication-title: Cardiology
  doi: 10.1159/000316050
– ident: 10.1016/j.amjcard.2025.07.040_bib0002
– volume: 53
  start-page: 174
  issue: 2
  year: 2006
  ident: 10.1016/j.amjcard.2025.07.040_bib0015
  article-title: Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs
  publication-title: J Pharmacol Toxicol Methods
  doi: 10.1016/j.vascn.2005.07.002
– ident: 10.1016/j.amjcard.2025.07.040_bib0012
– volume: 54
  start-page: 188
  issue: 2
  year: 2002
  ident: 10.1016/j.amjcard.2025.07.040_bib0013
  article-title: The significance of QT interval in drug development
  publication-title: Br J Clin Pharmacol
  doi: 10.1046/j.1365-2125.2002.01627.x
– volume: 20
  start-page: 776
  issue: 7
  year: 2000
  ident: 10.1016/j.amjcard.2025.07.040_bib0006
  article-title: Dofetilide, a new class III antiarrhythmic agent
  publication-title: Pharmacotherapy
  doi: 10.1592/phco.20.9.776.35208
– volume: 70
  start-page: 1432
  issue: 18
  year: 1992
  ident: 10.1016/j.amjcard.2025.07.040_bib0011
  article-title: Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris
  publication-title: Am J Cardiol
  doi: 10.1016/0002-9149(92)90295-A
SSID ssj0001156
Score 2.4902294
Snippet •Dofetilide administered intravenously has a rapid onset of action and the dose of dofetilide is proportional to the prolongation in cardiac repolarization as...
Dofetilide's action is inhibition of the potassium channel (IKr) which causes a delay of repolarization as seen on the ECG as QTc prolongation and is its...
SourceID pubmed
crossref
elsevier
SourceType Index Database
Publisher
StartPage 38
Title The Time Course of Repolarization Effects of Intravenous Dofetilide: A Pure Class III Antiarrhythmic Agent
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0002914925004503
https://dx.doi.org/10.1016/j.amjcard.2025.07.040
https://www.ncbi.nlm.nih.gov/pubmed/40769288
Volume 257
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwELUQSIgLYt8rH7imzeI4MbeogBoQiANIvUWuF5GKLiopEhe-nZksLVwAccxiyxo7M2-cec-EnAfKcIgMGulnkKB40jpC8tAxnhVMMZdFJcv17p73nthNP-yvkG7DhcGyytr3Vz699Nb1nU5tzc40z5Hj6_rCQ3E9xCWl4idjEerntz-WZR6AeHgDgfHtJYunM2zL0VDBRECa6IelhifugfwYn74En-stslmjRppUA9smK2a8Q9bv6v_iu2QIs02RzUHxDLpXQyeWIrSGtLXmWdJKpvgVn6S4oftWirPSy4k1Rf6Sa3NBE_own0EXCKhpmqY0GcP3P5s9vxfPo1zRBGlYe-Tp-uqx23PqUxQcBdilcDhEH-tbDaFYS6Fd5Q9cT3PrSchUYk9JSJkUJB088KWW0SBQbBBFQiguQxVoG-yT1fFkbA4JFdZwJgGhAKxgKtbSMs3jWHt4BnvExRFpN7bLppVYRtZUkQ2z2tgZGjtzowyMfUR4Y-GsYYKC78rAnf_WMF40_LZc_tL0oJrKxRAhp-XCj-Pj_3d6QjbwCutcvPCUrBazuTkDtFIMWuVybJG1JL3t3X8CZU_nmg
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwELUQSMAFse_gA9e0WRwn5lYVUAMUcQCJm-V6EamgRSVF4sK3M5OF5QKIaxxb1tiaec-eNybkKNKWQ2QwKD8DghIo5wnFY88GTjDNfJaUKtf-Fe_dsvO7-G6GdBstDKZV1r6_8umlt66_tGtrtp_yHDW-figCLK6HuAQrfs6xOEpwa7fePvM8APLwBgPj758ynvawpR6HGlYCeGIYl0U88RDkxwD1JfqcLZOlGjbSTjWzFTJjR6tkvl9fjK-RISw3RTkHxUfoni0dO4rYGnhrLbSkVZ3iZ2zJ8ET3pazOSk_Gzhb5Q27sMe3Q6-kEhkBETbMso50ROIDJ5P61uH_MNe2gDmud3J6d3nR7Xv2MgqcBvBQeh_DjQmcgFhsljK_DgR8Y7gIFVCUNtALOpIF18ChURiWDSLNBkgihuYp1ZFy0QWZH45HdIlQ4y5kCiAK4gunUKMcMT1MT4CPsCRfbpNXYTj5V1TJkk0Y2lLWxJRpb-okEY28T3lhYNlJQcF4S_PlvHdOPjt_2y1-6blZL-TFFILVchGm68_9BD8lC76Z_KS-zq4tdsogtmPQSxHtktphM7T5Al2JwUG7Nd9VK6TA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Time+Course+of+Repolarization+Effects+of+Intravenous+Dofetilide%3A+A+Pure+Class+III+Antiarrhythmic+Agent&rft.jtitle=The+American+journal+of+cardiology&rft.au=Molnar%2C+Janos&rft.au=Somberg%2C+John+C.&rft.date=2025-12-15&rft.pub=Elsevier+Inc&rft.issn=0002-9149&rft.volume=257&rft.spage=38&rft.epage=42&rft_id=info:doi/10.1016%2Fj.amjcard.2025.07.040&rft.externalDocID=S0002914925004503
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9149&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9149&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9149&client=summon